In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment algorithm is rapidly evolving, driven by the approval of multiple PARP inhibitors, including the market entry of Clovis Oncology’s Rubraca and Tesaro’s Zejula in the United States. Several areas of high unmet need—in particular, new treatment options for platinum-resistant or refractory ovarian cancer—offer significant commercial opportunity for innovative agents. Multiple immune checkpoint inhibitor combination therapies are in late-phase development for ovarian cancer and could significantly alter the treatment paradigm. This content provides insight on how treatment options for ovarian cancer are likely to change over the 2016-2026 forecast period. It also analyzes the current and future sales potential of drugs already in the market and those expected to be approved during the forecast period for ovarian ;
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts; physician surveys fielded to approximately 30 physicians from each of the major markets who treat at least five ovarian cancer patients per month.
Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).
Population segments in market forecast: Early-stage first-line, advanced-stage first-line, second-line platinum-sensitive, second-line platinum-resistant, third-line, fourth and subsequent lines.
Market forecast features: Using a proprietary patient-flow model incorporating mortality, we forecast population sizes and drug sales for all patient segments through 2026.